Search results
Order by most recent / most popular / relevance
Results: 1-10 of 19
EU continues revision and implementation of strict GMP rules
- Sidley Austin LLP
- -
- European Union
- -
- February 4 2013
In January 2013, three important developments regarding the EU's good manufacturing practice ("GMP") rules for medicinal products were made public:
European Commission publishes guidelines on use of food-related health claims
- Sidley Austin LLP
- -
- European Union
- -
- January 28 2013
On 25 January 2013, the European Commission's new guidelines regarding the use of food-related health claims ("Guidelines") were published in the
EU court rules on classification of certain borderline products as medical devices
- Sidley Austin LLP
- -
- European Union
- -
- December 3 2012
In a judgment published on November 22, 2012, the Court of Justice of the European Union (CJEU) confirmed that products intended for the investigation of physiological processes only fall within the scope of the EU Medical Device Directive (9342EEC), as implemented into EU Member State legislation, if the products are intended for a medical purpose
Significant overhaul of EU medical devices regime planned
- Sidley Austin LLP
- -
- European Union
- -
- October 29 2012
On 26 September 2012, the European Commission published the proposals for two new Regulations intended to replace the EU directives that govern medical devices intended to be placed on the EU market
EU court rejects national requirement for GM crop coexistence measures
- Sidley Austin LLP
- -
- European Union
- -
- September 26 2012
On 6 September 2012, the Court of Justice of the European Union (CJEU) issued an important ruling in a case referred to it by Italy’s highest administrative court, the Consliglio di Stato
Extended scope EU Penalties Regulation enters into force
- Sidley Austin LLP
- -
- European Union
- -
- July 13 2012
As of 2 July 2012, infringements of the EU’s paediatric and new pharmacovigilance rules fall within the scope of the revised EU Penalties Regulation and are now subject to financial penalties of up to 5 percent of the marketing authorization holder’s annual EU turnover
European Parliament calls for additional medical device safety measures
- Sidley Austin LLP
- -
- European Union
- -
- June 18 2012
On 14 June 2012, the European Parliament (“EP”) adopted a Resolution calling on EU Member States and the European Commission to introduce and implement new measures aimed at ensuring the safety of medical devices
Updates on international pricing issues for pharmaceutical and biologic products
- Sidley Austin LLP
- -
- China, European Union, France, Germany, United Kingdom, USA
- -
- May 18 2012
Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies
Opportunities to comment on the implementation of the EU Falsified Medicines Directive
- Sidley Austin LLP
- -
- European Union
- -
- January 31 2012
The European Commission is currently taking the necessary steps to implement the provisions of the EU Falsified Medicines Directive (201162EU), published on 1 July 2011 and amending the EU Medicinal Products Directive (200183EC
Falsified Medicines Directive public consultation on “safety features”
- Sidley Austin LLP
- -
- European Union
- -
- December 22 2011
The EU’s Falsified Medicines Directive (Directive 201162EU) forms part of the Pharma Package, a series of measures proposed by the European Commission in December 2008
Current Search
Suggested Facets
Author
- Carl-Michael Simon (1)
- James C. Stansel (8)
- Katherine Wang (1)
- Kristina Nordlander (7)
- Maarten Meulenbelt (13)
- Maurits J.F. Lugard (15)
- Scott Bass (7)
- Trevor L. Wear (1)
- Vincenzo Salvatore (7)
- William Sarraille (1)
